Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 11:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 88 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Januvia (Sitagliptin) 100 mg Clear all
Completed Phase 3 Interventional Results available

Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus.

NCT02849080
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
semaglutide, sitagliptin
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
504 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
37
States / cities
Glendale, Arizona • Phoenix, Arizona • Lancaster, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2022 · Synced Oct 5, 2026, 11:33 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (Explores What the Body Does to the Drug), and Pharmacodynamics (Explores What a Drug Does to the Body) of JNJ-38431055 in Volunteers With Type 2 Diabetes Mellitus

NCT00871507
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
JNJ-38431055 Dose 1, Sitagliptin 100 mg, Placebo, JNJ-38431055 Dose 2
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
25 Years to 60 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
2
States / cities
Fort Myers, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 22, 2014 · Synced Oct 5, 2026, 11:33 PM EDT
Completed Not applicable Interventional Results available

Effect of Chronic Incretin-based Therapy in Cystic Fibrosis

NCT01879228
View directory record Official record
Conditions
Cystic Fibrosis, Pancreatic Insufficiency
Interventions
Sitagliptin, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 8, 2022 · Synced Oct 5, 2026, 11:33 PM EDT
Completed Phase 4 Interventional Results available

The Effect of Dipeptidyl Peptidase 4 Inhibition on Growth Hormone Secretion in Women With Polycystic Ovarian Syndrome

NCT02122380
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
Sitagliptin, Placebo
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 8, 2020 · Synced Oct 5, 2026, 11:33 PM EDT
Completed Not applicable Interventional Results available

Treatment of Diabetes After Gastric Bypass With Sitagliptin

NCT01512797
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Sitagliptin phosphate, Placebo
Drug · Other
Lead sponsor
Blandine Laferrere
Other
Eligibility
18 Years to 70 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 22, 2019 · Synced Oct 5, 2026, 11:33 PM EDT
Completed Phase 2 Interventional

A Study Comparing the Safety, Tolerance, and Efficacy of Various Doses of SK-0403 Versus Placebo and Sitagliptin 100 mg in Patients Not Well-Controlled on Metformin Therapy

NCT01169090
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
SK-0403, Placebo, Sitagliptin
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
620 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
40
States / cities
Birmingham, Alabama • Huntsville, Alabama • Muscle Shoals, Alabama + 37 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2011 · Synced Oct 5, 2026, 11:33 PM EDT
Completed Phase 3 Interventional Results available

The CANTATA-MP Trial (CANagliflozin Treatment and Trial Analysis - Metformin and Pioglitazone)

NCT01106690
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, Canagliflozin, Sitagliptin, Metformin, Pioglitazone
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
41
States / cities
Anniston, Alabama • Phoenix, Arizona • Tucson, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2013 · Synced Oct 5, 2026, 11:33 PM EDT
Completed Phase 4 Interventional Results available

Effect of DPP4 Inhibition on Vasoconstriction

NCT02639637
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Sitagliptin, Placebo, Neuropeptide Y, Enalaprilat, Valsartan 160mg
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 27, 2018 · Synced Oct 5, 2026, 11:33 PM EDT
Terminated Phase 4 Interventional Results available

Use of Sitagliptin to Decrease Microalbuminuria

NCT02048904
View directory record Official record
Conditions
Type 2 Diabetes, Microalbuminuria
Interventions
Sitagliptin, Placebo
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years to 75 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 10, 2017 · Synced Oct 5, 2026, 11:33 PM EDT
Completed Phase 4 Interventional Results available

Cardiovascular Effects of GLP-1 Receptor Activation

NCT03101930
View directory record Official record
Conditions
Obesity, PreDiabetes
Interventions
Liraglutide, Sitagliptin, hypocaloric diet, Placebos, Exendin (9-39)
Drug · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
329 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 18, 2022 · Synced Oct 5, 2026, 11:33 PM EDT
Completed Phase 4 Interventional Results available

Anti-Diabetic Medications to Fight PD and LBD

NCT06263673
View directory record Official record
Conditions
Lewy Body Dementia, Parkinson Disease
Interventions
Sitagliptin, Dapagliflozin, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
45 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 5, 2026, 11:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Drug Interaction Study of Dapagliflozin and Glimepiride or Sitagliptin in Healthy Subjects

NCT00842556
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Dapagliflozin, Glimepiride, Sitagliptin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 17, 2016 · Synced Oct 5, 2026, 11:33 PM EDT
Completed Phase 2 Interventional Results available

Study of Safety and Efficacy of PF-04991532 in Subjects With Type 2 Diabetes

NCT01338870
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, 25 mg PF-04991532, 75 mg PF-04991532, 150 mg PF-04991532, 300 mg PF-04991532, Sitagliptin 100 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
25
States / cities
Little Rock, Arkansas • Roseville, California • Denver, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2013 · Synced Oct 5, 2026, 11:33 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

DPP-4 Inhibition and TZD for DM Prevention

NCT01006018
View directory record Official record
Conditions
Prediabetic State
Interventions
Sitagliptin + Pioglitazone PLACEBO, Sitagliptin + Pioglitazone, PLACEBO
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 5, 2013 · Synced Oct 5, 2026, 11:33 PM EDT
Not yet recruiting Phase 4 Interventional Accepts healthy volunteers

Pharmacogenetics of Response to Sitagliptin (PRS)

NCT06813014
View directory record Official record
Conditions
Diabetes
Interventions
Oral Glucose Tolerance Test
Procedure
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2032
U.S. locations
1
States / cities
Lancaster, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 5, 2026, 11:33 PM EDT
Terminated Phase 4 Interventional Results available

Fatty Liver Study in Patients With Type II Diabetes

NCT02365233
View directory record Official record
Conditions
Type II Diabetes, Nonalcoholic Fatty Liver
Interventions
DPP4 inhibitor, Pioglitazone, Lantus insulin
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Oct 5, 2026, 11:33 PM EDT
Withdrawn Phase 3 Interventional

A Study to Evaluate ITCA 650 Compared to Sitagliptin for the Treatment of Type 2 Diabetes

NCT01455909
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
ITCA 650 60 mcg/day, sitagliptin
Drug
Lead sponsor
Intarcia Therapeutics
Industry
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Hayward, California
Source: ClinicalTrials.gov public record
Updated Dec 25, 2012 · Synced Oct 5, 2026, 11:33 PM EDT
Completed Phase 3 Interventional Results available

The CANTATA-M (CANagliflozin Treatment and Trial Analysis - Monotherapy) Trial

NCT01081834
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Canagliflozin, Placebo, Sitagliptin
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
678 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
24
States / cities
Phoenix, Arizona • Concord, California • Greenbrae, California + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 5, 2026, 11:33 PM EDT
Completed Phase 1 Interventional Results available

Study Of Two Dosing Regimens Of PF-04937319 Compared To An Approved Agent (Sitagliptin) In Patients With Type 2 Diabetes

NCT01933672
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
PF-04937319 once-daily, PF-04937319 split-dose, Sitagliptin once-daily
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
8
States / cities
DeLand, Florida • South Miami, Florida • High Point, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2016 · Synced Oct 5, 2026, 11:33 PM EDT
Completed Phase 2 Interventional Results available

Empagliflozin (BI 10773) in Type Two Diabetes (T2D) Patients, Open Label Extension

NCT00881530
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
BI 10773, Metformin, Sitagliptin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
12
States / cities
Mission Viejo, California • Spring Valley, California • Walnut Creek, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2014 · Synced Oct 5, 2026, 11:33 PM EDT
Completed Phase 4 Interventional Results available

Effects of Sitagliptin on Endothelial Function in Type 2 Diabetes on Background Metformin Therapy

NCT01859793
View directory record Official record
Conditions
Diabetes, Atherosclerosis
Interventions
sitagliptin, Placebo
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
21 Years to 70 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 21, 2016 · Synced Oct 5, 2026, 11:33 PM EDT
Completed Phase 4 Interventional Results available

Sitagliptin in Non-Diabetic Patients Undergoing General Surgery

NCT02741687
View directory record Official record
Conditions
Hyperglycemia
Interventions
Sitagliptin, Placebo, Supplemental insulin (insulin lispro), Supplemental insulin (insulin aspart), Long acting basal insulin (insulin detemir), Long acting basal insulin (insulin glargine)
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 27, 2018 · Synced Oct 5, 2026, 11:33 PM EDT
Terminated Phase 3 Interventional

Safety and Efficacy Study of Dutogliptin in Subjects With Type 2 Diabetes Mellitus on a Background Medication of Metformin

NCT00998686
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
dutogliptin, sitagliptin
Drug
Lead sponsor
Phenomix
Industry
Eligibility
18 Years to 85 Years
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
23
States / cities
Montgomery, Alabama • Tempe, Arizona • Anaheim, California + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2010 · Synced Oct 5, 2026, 11:33 PM EDT
Completed Phase 3 Interventional Results available

24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years

NCT00976937
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Lixisenatide (AVE0010), Lixisenatide Placebo, Pen auto-injector, Sitagliptin, Sitagliptin Placebo, Metformin
Drug · Device
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 49 Years
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
21
States / cities
Montgomery, Alabama • Muscle Shoals, Alabama • Mesa, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2016 · Synced Oct 5, 2026, 11:33 PM EDT